Public Sector Pension Investment Board Acquires 500 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Public Sector Pension Investment Board increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,341 shares of the biopharmaceutical company’s stock after buying an additional 500 shares during the period. Public Sector Pension Investment Board’s holdings in Regeneron Pharmaceuticals were worth $4,563,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. SteelPeak Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 173.0% in the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares during the last quarter. Mizuho Securities USA LLC grew its position in Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP increased its stake in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. raised its holdings in Regeneron Pharmaceuticals by 50.8% in the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock worth $10,082,000 after buying an additional 3,231 shares during the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth about $1,334,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on REGN. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Wells Fargo & Company cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Citigroup assumed coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They issued a “neutral” rating and a $895.00 price target for the company. Evercore ISI dropped their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Finally, Oppenheimer decreased their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $750.22 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The firm has a market capitalization of $82.44 billion, a price-to-earnings ratio of 18.57, a PEG ratio of 2.89 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The business has a 50 day simple moving average of $905.64 and a 200-day simple moving average of $1,019.64.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.